drugset / Trial / NCT00287066

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

NCT00287066

Phase 3 Terminated 22 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes

Timeline

Start
2006-02
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Inhaled
Subject Insulin Protein / enzyme biologic Intravenous